Therefore, the role of TNFSF14 in NSCLC metastasis is controversial and warrants further evidence; the mAb targeting TNFSF14 is under clinical trial, and the tolerance to TNFSF14 and combination effects are unclear. Here, TNFSF14 is linked to non-small cell lung carcinoma.